- 3922 – lorlatinib by Pfizer
- alectinib – Alecensa from Chugai – Roche – GenenTech
- Anaplastic Large-Cell Lymphomas
- AP26113 – brigatinib from Ariad
- ASP3026 from Astellas
- Brain metastases
- ceritinib – Zykadia from Novartis
- crizotinib – Xalkori from Pfizer
- Lung cancer
- PLB1003 – Beijing Pearl Biotechnology
- Potential Treatments
- Regulatory applications & approvals
- Resistance to treatment
- RXDX-101 – entrectinib – by Ignyta
- Side Effects
- TPX-0005: TP Therapeutics
- TSR-011 from Tesaro
- X-396 – ensartinib from Xcovrery
Category Archives: Uncategorized
Here is an article on a presentation by Dr. Ou on potential ALK inhibitor treatments for brain metastases http://www.onclive.com/conference-coverage/ilcc-2014/Next-Generation-ALK-Inhibitors-Effective-in-Patients-With-Brain-Metastases
Here is the link for the video by OncLive. https://m.youtube.com/watch?v=UAYcOohlRcI
This article in Nature covers EGFR and ALK mutations and resistance mechanisms. http://www.nature.com/nrclinonc/journal/vaop/ncurrent/abs/nrclinonc.2014.104.html
71 ALK+ NSCLC patients enrolled out of 125 patients. Main adverse event of concern is early onset pulmonary (lung) symptoms. Out of 125 patients this happened 10% and occurred most frequently at doses of 180 mg or higher. New protocol: … Continue reading
Genentech/Roche has recently done two studies involving Avastin and Erlotinib. In November 2013 they released a study of over 1,100 patients comparing Avastin with and without Erlotinib. Critically I believe that the patients were not screened for the EGFR mutation. … Continue reading
Uptodate’s entry on ALK inhibitors was updated in early May on Ceritinib’s FDA approval.
Oncoethix, a European consortium, has published a presentation on preclinical results for a new ALK inhibitor called OTX015. When combined with Crizotinib it has greater inhibitory effect. It also inhibits: BET and BRD families of reader proteans. The BET inhibition … Continue reading
This post will cover various articles on possible causes of developed resistance.
This post will include links to articles about the treatment of tumors that have developed resistance to a targeted therapy.
This post is for links to articles about disease flare (the rapid increase in cancerous growth after a kinase inhibitor is discontinued).